Efineptakin alfa

Efineptakin alfa (NT-17) is a long-acting recombinant human IL-7. Efineptakin alfa supports the proliferation and survival CD4+ and CD8+ cells in both human and mice. Efineptakin alfa can be used for glioblastoma research[1].

Research Areas >> Cancer

Signaling Pathways >> Immunology/Inflammation >> Interleukin Related

IL7R

Efineptakin alfa (10mg /kg，肌肉注射，单次) 联合 SLC-3010 (1.8 mg/kg，静脉注射，单次)抑制 MC38 荷瘤小鼠的肿瘤生长[2]。 Efineptakin alfa (10 mg/kg) 在原位胶质瘤荷瘤小鼠中，可减轻放疗相关的淋巴细胞减少，增加全身和肿瘤中的细胞毒性 CD8 T 淋巴细胞，并提高原位胶质瘤荷瘤小鼠的存活率[1]。 Animal Model: C57BL/6 mice bearing intracranial tumors (GL261 or CT2A)[1] Dosage: 10 mg/kg Administration: On the final day of RT (radiotherapy, 1.8 Gy/day × 5 days) completion Result: Increased T lymphocytes in the lymph nodes, thymus, and spleen, enhanced IFNγ production, and decreased Tregs in the tumor which was associated with a significant increase in survival. Enhanced central memory and effector memory CD8 T cells in lymphoid organs and tumor. Decreased progenitor cells in the bone marrow.

[1]. Campian JL, et al. Long-Acting Recombinant Human Interleukin-7, NT-I7, Increases Cytotoxic CD8 T Cells and Enhances Survival in Mouse Glioma Models. Clin Cancer Res. 2022 Mar 15;28(6):1229-1239.  

[2]. Seungtae Baek, et al. rhIL-7-hyFc (efineptakin alfa; NT-I7) enhances the anti-tumor response when combined with hIL-2/TCB2c complex. 2022 AACR Abstract #4199.